With the huge potential of China's ophthalmology market, it faces three major challenges

With the advent of aging and consumption upgrades and the advent of the electronic age, people are paying more and more attention to eye health, which has also rapidly promoted the development of the ophthalmology field
.
According to data from Frost & Sullivan and "China Medical Device Industry Development Report", the overall scale of China's ophthalmology market in 2019 has reached 170 billion yuan, of which the ophthalmic device market is 26.
7 billion yuan, accounting for 16%; the ophthalmic medicine market is 19.
3 billion yuan, Accounted for 11%
.
Industry analysis believes that as China’s aging rate increases, work intensity increases, and life>
.
In fact, while the current ophthalmology market is experiencing rapid growth, a large number of companies are accelerating their entry into this market
.
Recently, many pharmaceutical companies have announced new breakthroughs in this field
.
Recently, China's National Food and Drug Administration (NMPA) announced that the tafluprost eye drops declared by Chengdu Shengdi Pharmaceutical Co.
, Ltd.
, a subsidiary of Hengrui Pharmaceuticals, has been approved for marketing, becoming the first imitation of the product
.
Data show that tafluprost is a prostaglandin analogue and a selective FP prostaglandin receptor agonist, which can reduce intraocular pressure by increasing the uveoscleral aqueous humor outflow, and is used to reduce open-angle glaucoma And elevated intraocular pressure in patients with ocular hypertension
.
After medication, it will act on the uveoscleral pathway of aqueous humor drainage to loosen the interstitial space and reduce the resistance of aqueous humor drainage
.
At present, no generic drug of tafluprostaglandin eye drops has been approved for marketing in China, and there are fewer manufacturers of this product, with only two companies, Shengdi Pharmaceutical and Sichuan Kelun
.
This time, Shengdi Medicine's tafluprost eye drops are planned to be included in the priority review, which means that the drug is expected to be approved for marketing at an accelerated rate, thereby bringing new choices to more glaucoma patients
.
On October 29, Osaikang also issued an announcement stating that its dual-targeting anti-VEGF-A humanized monoclonal antibody-Ang-2 inhibitor peptide fusion protein with independent intellectual property rights, ASKG712 clinical trial application for injection was accepted by NMPA, The intended indications include Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion- Macular Edema (Retinal Vein Occlusion- Macular Edema) RVO-ME) and so on
.
It should be noted that although China's ophthalmology market is developing rapidly, its potential is also very large
.
But as a whole, it is still in its infancy and still faces three challenges
.
First of all, although people are paying more and more attention to eye health, there is still much room for improvement in the public's understanding and attention to eye health knowledge such as cataracts and myopia
.
Secondly, the training and education of ophthalmology clinicians is also a major challenge for the current development of the ophthalmology field
.
In addition, there is a big challenge on the payment side
.
But in general, given that the current penetration rate of treatment for cataracts, glaucoma, refractive correction and other diseases is low, and the number of patients continues to increase, the industry predicts that China’s future eye disease diagnosis and treatment has at least two times more room for growth.
, By 2025, the size of China's ophthalmology market may exceed 310 billion at least, and this market will attract more and more companies to enter the market
.
Among them, companies with advantages in specialty promotion may have higher voice and channel advantages and usher in more development opportunities
.